Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 126.69M P/E - EPS this Y 114.30% Ern Qtrly Grth -
Income -1.35M Forward P/E -28.17 EPS next Y 800.00% 50D Avg Chg 5.00%
Sales 85.58M PEG - EPS past 5Y - 200D Avg Chg 3.00%
Dividend N/A Price/Book 4.52 EPS next 5Y - 52W High Chg -25.00%
Recommedations 1.70 Quick Ratio 2.04 Shares Outstanding 75.93M 52W Low Chg 47.00%
Insider Own 35.60% ROA -2.68% Shares Float 48.94M Beta 1.86
Inst Own 22.53% ROE -4.67% Shares Shorted/Prior 2.95M/3.23M Price 1.69
Gross Margin 60.82% Profit Margin -1.58% Avg. Volume 75,853 Target Price 6.67
Oper. Margin -1.13% Earnings Date Nov 6 Volume 47,058 Change -1.17%
About ChromaDex Corporation

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

ChromaDex Corporation News
12/24/24 4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
12/20/24 3 US Growth Companies With High Insider Ownership Expecting Up To 119% Earnings Growth
12/20/24 Exploring December 2024's US Undervalued Small Caps With Insider Buying
12/10/24 Even though ChromaDex (NASDAQ:CDXC) has lost US$73m market cap in last 7 days, shareholders are still up 389% over 1 year
12/03/24 ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
11/22/24 ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
11/19/24 3 US Stocks Estimated To Be Trading At Discounts Ranging From 13% To 41%
11/15/24 3 US Growth Companies With Strong Insider Confidence
11/14/24 ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
11/08/24 What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now?
11/08/24 5 Stocks With Recent Price Strength to Tap Wall Street Rally
11/07/24 ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
11/07/24 Shareholders Can Be Confident That ChromaDex's (NASDAQ:CDXC) Earnings Are High Quality
11/05/24 ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?
11/02/24 ChromaDex Third Quarter 2024 Earnings: Beats Expectations
11/01/24 ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
10/31/24 ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates
10/31/24 ChromaDex: Q3 Earnings Snapshot
10/31/24 ChromaDex Corporation Reports Third Quarter 2024 Financial Results
10/29/24 ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Chau Hoi Shuen Solina Holly 10% Owner 10% Owner Sep 30 Buy 1.25 960,000 1,200,000 7,885,641 10/03/22
Chau Hoi Shuen Solina Holly 10% Owner 10% Owner Jun 16 Buy 1.6636 60,037 99,878 6,925,641 06/21/22
Fried Robert N CEO CEO Mar 16 Buy 2.16 25,000 54,000 88,001 03/16/22